Literature DB >> 23774880

Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection.

Maxwel M Omenda1, Caitlin Milligan, Katherine Odem-Davis, Ruth Nduati, Barbra A Richardson, John Lynch, Grace John-Stewart, Julie Overbaugh.   

Abstract

: Little is known about the efficiency of vertical transfer of HIV-1-specific antibodies. Antibody levels in plasma from 60 mother-infant pairs near the time of birth, including 14 breast-feeding transmission pairs, were compared. The envelope-binding titers were strongly correlated (r = 0.91, P < 0.0001) and similar (1.4-fold greater in maternal plasma) between a mother and her corresponding infant as were the neutralizing antibody (Nab) levels (r = 0.80, P < 0.0001; 1.3-fold higher), suggesting efficient transfer. There was no significant difference in Nab responses between transmitting and nontransmitting mothers, although there was a trend for transmitting mothers to have higher HIV-1-specific Nabs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774880      PMCID: PMC3805370          DOI: 10.1097/QAI.0b013e31829f6e41

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  15 in total

1.  Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission.

Authors:  J L Lathey; J Tsou; K Brinker; K Hsia; W A Meyer; S A Spector
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

2.  Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.

Authors:  Ruth Dickover; Eileen Garratty; Karina Yusim; Catherine Miller; Bette Korber; Yvonne Bryson
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya.

Authors:  J R Neilson; G C John; J K Carr; P Lewis; J K Kreiss; S Jackson; R W Nduati; D Mbori-Ngacha; D D Panteleeff; S Bodrug; C Giachetti; M A Bott; B A Richardson; J Bwayo; J Ndinya-Achola; J Overbaugh
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

5.  Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina.

Authors:  Pushpa Jayaraman; Deepika Mohan; Patricia Polacino; LaRene Kuller; Nadeem Sheikh; Helle Bielefeldt-Ohmann; Barbra Richardson; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Med Primatol       Date:  2004-10       Impact factor: 0.667

6.  Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3.

Authors:  Pushpa Jayaraman; Tuofu Zhu; Lynda Misher; Deepika Mohan; LaRene Kuller; Patricia Polacino; Barbra A Richardson; Helle Bielefeldt-Ohmann; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.

Authors:  K Broliden; E Sievers; P A Tovo; V Moschese; G Scarlatti; P A Broliden; C Fundaro; P Rossi
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

8.  Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype.

Authors:  R N Husson; Y Lan; E Kojima; D Venzon; H Mitsuya; K McIntosh
Journal:  J Pediatr       Date:  1995-06       Impact factor: 4.406

9.  HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.

Authors:  Jennifer Mabuka; Ruth Nduati; Katherine Odem-Davis; Dylan Peterson; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2012-06-14       Impact factor: 6.823

10.  Cross-reactive broadly neutralizing antibodies: timing is everything.

Authors:  Zelda Euler; Hanneke Schuitemaker
Journal:  Front Immunol       Date:  2012-07-20       Impact factor: 7.561

View more
  14 in total

1.  Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.

Authors:  Bonnie Phillips; Genevieve G Fouda; Josh Eudailey; Justin Pollara; Alan D Curtis; Erika Kunz; Maria Dennis; Xiaoying Shen; Camden Bay; Michael Hudgens; David Pickup; S Munir Alam; Amir Ardeshir; Pamela A Kozlowski; Koen K A Van Rompay; Guido Ferrari; M Anthony Moody; Sallie Permar; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

2.  Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Authors:  Sallie R Permar; Youyi Fong; Nathan Vandergrift; Genevieve G Fouda; Peter Gilbert; Robert Parks; Frederick H Jaeger; Justin Pollara; Amanda Martelli; Brooke E Liebl; Krissey Lloyd; Nicole L Yates; R Glenn Overman; Xiaoying Shen; Kaylan Whitaker; Haiyan Chen; Jamie Pritchett; Erika Solomon; Emma Friberg; Dawn J Marshall; John F Whitesides; Thaddeus C Gurley; Tarra Von Holle; David R Martinez; Fangping Cai; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Raul Louzao; Samantha Wilkes; Saheli Datta; Marcella Sarzotti-Kelsoe; Hua-Xin Liao; Guido Ferrari; S Munir Alam; David C Montefiori; Thomas N Denny; M Anthony Moody; Georgia D Tomaras; Feng Gao; Barton F Haynes
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

Review 3.  Antibodies for prevention of mother-to-child transmission of HIV-1.

Authors:  Genevieve G Fouda; M Anthony Moody; Sallie R Permar
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

4.  Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.

Authors:  David R Martinez; Nathan Vandergrift; Ayooluwa O Douglas; Erin McGuire; John Bainbridge; Nathan I Nicely; David C Montefiori; Georgia D Tomaras; Genevieve G Fouda; Sallie R Permar
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

Review 5.  Mother-infant HIV transmission: do maternal HIV-specific antibodies protect the infant?

Authors:  Julie Overbaugh
Journal:  PLoS Pathog       Date:  2014-08-21       Impact factor: 6.823

6.  Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies.

Authors:  Chuanxi Fu; Long Lu; Hao Wu; Jeffrey Shaman; Yimin Cao; Fang Fang; Qiongying Yang; Qing He; Zhicong Yang; Ming Wang
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

Review 7.  The Role of Maternal HIV Envelope-Specific Antibodies and Mother-to-Child Transmission Risk.

Authors:  Ayooluwa O Douglas; David R Martinez; Sallie R Permar
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 8.  Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

Authors:  Harini Subbaraman; Merle Schanz; Alexandra Trkola
Journal:  Retrovirology       Date:  2018-07-28       Impact factor: 4.602

Review 9.  The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Authors:  Martine Braibant; Francis Barin
Journal:  Retrovirology       Date:  2013-10-07       Impact factor: 4.602

10.  Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.

Authors:  Caitlin Milligan; Maxwel M Omenda; Vrasha Chohan; Katherine Odem-Davis; Barbra A Richardson; Ruth Nduati; Julie Overbaugh
Journal:  mBio       Date:  2016-02-02       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.